Greaves Malcolm W, Tan Kian Teo
St Johns Institute of Dermatology, St Thomas' Hospital, London, UK.
Clin Rev Allergy Immunol. 2007 Oct;33(1-2):134-43. doi: 10.1007/s12016-007-0038-3. Epub 2007 Sep 18.
Chronic urticaria is an umbrella term, which encompasses physical urticarias, chronic "idiopathic" urticaria and urticarial vasculitis. It is important to recognize patients with physical urticarias as the investigation and treatment differs in important ways from patients with idiopathic chronic urticaria or urticarial vasculitis. Although relatively uncommon, urticarial vasculitis is an important diagnosis to make and requires histological confirmation by biopsy. Underlying systemic disease and systemic involvement, especially of the kidneys, should be sought. It is now recognized that chronic "idiopathic" urticaria includes a subset with an autoimmune basis caused by circulating autoantibodies against the high affinity IgE receptor (FceR1) and less commonly against IgE. Although the autologous serum skin test has been proven useful in prompting search for and characterization of circulating wheal-producing factors in chronic urticaria, its specificity as a screening test for presence of functional anti-FceR1 is low, and confirmation by demonstration of histamine-releasing activity in the patient's serum must be the benchmark test in establishing this diagnosis. Improved screening tests are being sought; for example, ability of the chronic urticaria patient's serum to evoke expression of CD 203c on donor human basophils is showing some promise. The strong association between autoimmune thyroid disease and autoimmune urticaria is also an area of ongoing research. Drug treatment continues to be centered on the H1 antihistamines, and the newer second-generation compounds appear to be safe and effective even in off-label dosage. Use of systemic steroids should be confined to special circumstances such as tapering regimens for acute flare-ups. Use of leukotriene antagonists is becoming popular, but the evidence for efficacy is conflicting. Cyclosporin is also effective and can be used in selected cases of autoimmune urticaria, and it is also effective in non-autoimmune cases, although less so.
慢性荨麻疹是一个统称,涵盖物理性荨麻疹、慢性“特发性”荨麻疹和荨麻疹性血管炎。识别患有物理性荨麻疹的患者很重要,因为其检查和治疗在重要方面与特发性慢性荨麻疹或荨麻疹性血管炎患者不同。虽然相对不常见,但荨麻疹性血管炎是一个需要做出的重要诊断,且需要通过活检进行组织学确认。应寻找潜在的全身性疾病和全身受累情况,尤其是肾脏受累。现在人们认识到,慢性“特发性”荨麻疹包括一个自身免疫性基础的亚组,由针对高亲和力IgE受体(FceR1)的循环自身抗体引起,较少见的是针对IgE的自身抗体。虽然自体血清皮肤试验已被证明有助于在慢性荨麻疹中寻找和鉴定循环性风团产生因子,但其作为功能性抗FceR1存在的筛查试验的特异性较低,通过证明患者血清中的组胺释放活性进行确认必须是确立该诊断的基准试验。正在寻求改进的筛查试验;例如,慢性荨麻疹患者血清诱发供体人嗜碱性粒细胞上CD 203c表达的能力显示出一些前景。自身免疫性甲状腺疾病与自身免疫性荨麻疹之间的强关联也是一个正在进行研究的领域。药物治疗仍然以H1抗组胺药为中心,较新的第二代化合物即使在非标签剂量下似乎也安全有效。全身性类固醇的使用应限于特殊情况,如急性发作的递减疗法。白三烯拮抗剂的使用越来越普遍,但疗效证据相互矛盾。环孢素也有效,可用于自身免疫性荨麻疹的特定病例,在非自身免疫性病例中也有效,尽管效果稍差。